by The Nephrology Drugs Market is primarily engaged in the development and commercialization of drugs for the treatment of kidney related disorders such as chronic kidney disease, urinary tract infections and kidney stones. Medications used in nephrology are classified as diuretics, amino glycosides, calcineurin inhibitors, antiproliferative agents and others. Rising prevalence of kidney disorders owing to diabetes, obesity and hypertension coupled with increasing awareness regarding early disease diagnosis is fueling the growth of the nephrology drugs market.
The Global Nephrology Drugs Market is estimated to be valued at US$ 26.9 Bn in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the Nephrology Drugs are Amgen Inc., F. Hoffmann-La Roche Ltd, Sanofi, Novartis AG, AstraZeneca, Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, AbbVie Inc., Genzyme Corporation, Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Shire Pharmaceuticals Limited, Keryx Biopharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd.
Growing for chronic kidney Nephrology Drugs Market Demand therapies owing to increasing geriatric population suffering from diabetes and hypertension is expected to boost the nephrology drugs market during the forecast period.
Major players in the nephrology drugs market are focusing on expansion in developing regions of Asia Pacific and Latin America through strategic collaborations and partnerships with local pharmaceutical companies.
Market Key Trends
Increasing popularity of biosimilars is one of the key trends being witnessed in the global nephrology drugs market. Biosimilars offer cost-effective alternatives to reference biologics and their uptake is growing steadily, especially in the developing regions. Growing acceptance of biosimilars for chronic kidney disease is expected to positively impact the overall nephrology drugs market during the forecast period.
Porter’s Analysis
Threat of new entrants: Entry of new players in the Nephrology Drugs Market Regional Analysis requires huge capital investment along with regulatory approvals which makes the threat low.
Bargaining power of buyers: Patients suffering from kidney diseases have limited options therefore bargaining power of buyers is low.
Bargaining power of suppliers: Major suppliers in this market are research labs and pharmaceutical companies. Suppliers have moderate bargaining power due to differentiated products.
Threat of new substitutes: There exist limited treatment substitutes for chronic kidney diseases making threat of substitutes low.
Competitive rivalry: Due to presence of many global as well as local players, competitive rivalry in the nephrology drugs market is high.
Geographical Regions
North America holds the major share in the nephrology drugs market in terms of value owing to high diagnosis and treatment rates of kidney diseases.
Asia Pacific is expected to be the fastest growing region during the forecast period driven by increasing healthcare expenditure, rising incidence of diabetes and hypertension, growing medical tourism, and expanding distribution channels.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
